Paclitaxel-Eluting vs. Sirolimus-Eluting Balloons

Coronary restenosis remains one of the main challenges in percutaneous transluminal coronary angioplasty (PTCA), especially nowadays, when procedures are increasingly complex and more stents are used, particularly in older patients.

Drug-eluting balloons (DEB) have proven to be beneficial in this scenario, according to several studies. Currently, there are paclitaxel- and sirolimus-eluting balloons, each with distinct characteristics. However, it is still unclear which of these drugs is superior or which circumstances would make one or the other more appropriate to use.

Researchers conducted a meta-analysis that included 1861 patients (from 5 randomized studies and 3 observational studies). Of these, 889 received paclitaxel-eluting balloons (PEB) and the rest received sirolimus-eluting balloons (SEB). Both de novo lesions and restenosis cases were included.

The assessment included clinical and angiographic events between 6 and 12 months of follow-up.

There were no significant differences between the groups in terms of the composite of cardiac death, myocardial infarction, or target vessel failure (odds ratio [OR] 1.01; 95% confidence interval [CI]: 0.75–1.35; I² = 0.0%). There were also no differences in cardiac mortality, myocardial infarction, or need for target lesion revascularization (TLR), which was consistent across both randomized and observational studies.

Read also: Plaque Morphology and Stent Elongation Assessed by OCT.

In the angiographic follow-up, patients who received PEB had a larger minimum luminal diameter compared to those who received SEB (0.10 mm, 95% CI: 0.02–0.17). This difference was more pronounced in de novo lesions than in restenosis cases.

Late lumen loss (the difference between the minimum luminal diameter during the procedure and at follow-up angiography) was also lower in patients treated with PEB compared with those who received SEB (-0.11 mm, 95% CI: -0.23 to 0.02; I² = 57.1%), although this difference was not statistically significant.

Conclusion:

At 9 and 12 months of follow-up, the rate of target lesion failure (TLF) was similar between the PEB and SEB groups. However, in the angiographic follow-up, the minimum luminal diameter was greater in patients who received PEB.

Original Title: Paclitaxel‐coated versus sirolimus‐coated balloon angioplasty for coronary artery disease: A systematic review and meta‐analysis.

Reference: Doosup Shin, et al. Catheter Cardiovasc Interv. 2024;104:425–436.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....